Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation identifier:
NCT02478892 (


Study Contact Information:

Principal investigator: 
Bryson Katona, MD
Phone: 855-216-0098

About this Study

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

What the Study Entails

People enrolled with the study will have annual screening for pancreatic cancer using one of two procedures: 

Participants will be screened and followed for ten years. 

Note: EUSs and MRIs performed on study participants are billed to insurance, and the study does not cover the cost of these procedures.

Study Site



This Study is Open To:

Men and women, age 18 years or older, are eligible if they have:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.